Gene Therapy Safety Faces Fresh Scrutiny After 2 China Deaths and 1 U.S. Brain Tumor Case
Updated
Updated · Gizmodo · Aug 17
Gene Therapy Safety Faces Fresh Scrutiny After 2 China Deaths and 1 U.S. Brain Tumor Case
3 articles · Updated · Gizmodo · Aug 17
Summary
Two child deaths in China and a U.S. report of a gene-therapy-linked brain tumor have pushed experts to reassess how aggressively the field should pursue speed versus safety.
Both China deaths occurred in investigator-initiated trials with lighter oversight, while the U.S. case involved a removable tumor detected four years after treatment at Children’s Hospital of Philadelphia.
Experts said AAV viral vectors remain central to gene therapy but can trigger dangerous immune reactions and, in under 1% of cases, insert DNA in ways that may activate cancer-causing genes.
Several specialists argued the answer is not broad deregulation but faster independent review, stronger monitoring, long-term follow-up, and fuller disclosure of adverse events so the field can learn from failures.
The debate is especially acute because many recipients are children with rapidly progressive, often fatal rare diseases, making treatment delays a risk alongside the therapies themselves.